DCTH Insider Trading

Insider Ownership Percentage: 17.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Delcath Systems Insider Trading History Chart

This chart shows the insider buying and selling history at Delcath Systems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$600k-$400k-$200k$0$200k$400k$600kTotal Insider BuyingTotal Insider Selling

Delcath Systems Share Price & Price History

Current Price: $15.29
Price Change: Price Increase of +0.84 (5.81%)
As of 05/13/2025 05:00 PM ET

This chart shows the closing price history over time for DCTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$14.45Closing price on 05/12/25:

Delcath Systems Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Delcath Systems (NASDAQ:DCTH)

61.12% of Delcath Systems stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DCTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$13Mbought$31MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More on Delcath Systems

Today's Range

Now: $15.29
Low: $14.33
High: $15.32

50 Day Range

MA: $12.33
Low: $10.39
High: $14.84

52 Week Range

Now: $15.29
Low: $5.96
High: $16.97

Volume

452,157 shs

Average Volume

453,641 shs

Market Capitalization

$511.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Who are the company insiders with the largest holdings of Delcath Systems?

Delcath Systems' top insider shareholders include:
  1. Gil Aharon (Director)
  2. Rosalind Advisors, Inc (Director)
  3. Gerard J Michel (CEO)
  4. Vojo Vukovic (Insider)
  5. John Purpura (COO)
  6. Sandra Pennell (SVP)
  7. John Richard Sylvester (Director)
Learn More about top insider investors at Delcath Systems.

Who are the major institutional investors of Delcath Systems?

Delcath Systems' top institutional shareholders include:
  1. Vanguard Group Inc. — 4.17%
  2. Vivo Capital LLC — 2.24%
  3. Invesco Ltd. — 1.19%
  4. AIGH Capital Management LLC — 0.78%
  5. Informed Momentum Co LLC — 0.62%
  6. Palisades Investment Partners LLC — 0.51%
Learn More about top institutional investors of Delcath Systems stock.

Which major investors are selling Delcath Systems stock?

In the last quarter, DCTH stock was sold by these institutional investors:
  1. AIGH Capital Management LLC
  2. Vivo Capital LLC
  3. Riverwater Partners LLC
  4. Jefferies Financial Group Inc.
  5. Simplex Trading LLC

Which major investors are buying Delcath Systems stock?

During the last quarter, DCTH stock was purchased by institutional investors including:
  1. Invesco Ltd.
  2. Vanguard Group Inc.
  3. Informed Momentum Co LLC
  4. Private Wealth Advisors LLC
  5. Capital Advisors Wealth Management LLC
  6. Cannon Global Investment Management LLC
  7. NBC Securities Inc.
  8. Baader Bank Aktiengesellschaft
Within the last year, these company insiders have bought Delcath Systems stock:
  1. Gil Aharon (Director)
  2. Rosalind Advisors, Inc (Director)
  3. Gerard J Michel (CEO)
  4. Vojo Vukovic (Insider)
  5. John Purpura (COO)
  6. Sandra Pennell (SVP)
  7. John Richard Sylvester (Director)
Learn More investors buying Delcath Systems stock.